Skip to main content
. Author manuscript; available in PMC: 2010 Dec 27.
Published in final edited form as: J Immunol. 2005 Jun 15;174(12):7904–7911. doi: 10.4049/jimmunol.174.12.7904

Figure 5. Changes in survival and weight loss of T. gondii-infected WT B6 and CD1d-deficient B6 mice treated with antibodies to deplete CD4+ cells.

Figure 5

(A) Weight loss. Values are mean +/− SD per cent initial body weights of mice given anti-CD4 or an isotype-matched control mAb (1 mg i.p. on days 0 and 2 relative to infection). The difference in body weight between anti-CD4-treated and control mAb-treated CD1d-deficient mice was significant (P<0.05) by day 12, but could not be tested beyond that time owing to the deaths of CD1d-deficient mice in the control mAb-treated group. (B) Survival. Anti-CD4-treated CD1d-deficient mice survived significantly (P<0.05) longer than control mAb-treated CD1d-deficient mice. In each experiment, there were 5 mice per treatment group.